Edgewise Therapeutics Inc (EWTX)

Jan 13, 2025, 8:00 AM EST - 4 days ago

Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025

Jan 7, 2025, 8:00 AM EST - 10 days ago

Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Dec 31, 2024, 2:09 PM EST - 17 days ago

Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data

Dec 16, 2024, 11:56 AM EST - 4 weeks ago

Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease

Dec 16, 2024, 6:00 AM EST - 4 weeks ago

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

Dec 5, 2024, 2:32 PM EST - 6 weeks ago

Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research

Nov 26, 2024, 6:00 AM EST - 7 weeks ago

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024

Nov 7, 2024, 8:00 AM EST - 2 months ago

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 1, 2024, 8:00 AM EDT - 3 months ago

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

Sep 30, 2024, 12:12 PM EDT - 3 months ago

Analysts Think There's Still Time To Get In On Edgewise

Sep 25, 2024, 11:50 AM EDT - 4 months ago

Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge

Sep 19, 2024, 10:19 AM EDT - 4 months ago

Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment

Sep 19, 2024, 7:00 AM EDT - 4 months ago

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

Sep 17, 2024, 4:01 PM EDT - 4 months ago

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time

Aug 8, 2024, 8:00 AM EDT - 5 months ago

Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 5, 2024, 2:38 PM EDT - 5 months ago

Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal

May 10, 2024, 8:00 AM EDT - 9 months ago

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024

May 9, 2024, 8:00 AM EDT - 9 months ago

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 7, 2024, 8:00 AM EDT - 9 months ago

Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

May 6, 2024, 8:00 AM EDT - 9 months ago

Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)

Apr 23, 2024, 8:00 AM EDT - 9 months ago

Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies

Apr 15, 2024, 4:05 PM EDT - 9 months ago

Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)

Mar 28, 2024, 8:00 AM EDT - 10 months ago

Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session

Mar 27, 2024, 8:00 AM EDT - 10 months ago

Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024

Mar 5, 2024, 8:00 AM EST - 11 months ago

Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024

Feb 28, 2024, 8:00 AM EST - 11 months ago

Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference

Feb 22, 2024, 8:00 AM EST - 11 months ago

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Feb 13, 2024, 8:00 AM EST - 1 year ago

Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)

Jan 19, 2024, 8:37 AM EST - 1 year ago

Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock

Jan 9, 2024, 8:39 AM EST - 1 year ago

Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 28, 2023, 3:00 PM EST - 1 year ago

Edgewise: DMD Data In The First Half Of 2024 Could Lead To Additional Testing

Dec 26, 2023, 5:21 PM EST - 1 year ago

Wedbush's Laura Chico talks biotech investing in 2024

IBB NBIX VRDN XBI

Dec 19, 2023, 8:00 AM EST - 1 year ago

Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024

Dec 18, 2023, 8:00 AM EST - 1 year ago

Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy Community

Nov 30, 2023, 8:00 AM EST - 1 year ago

Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA

Nov 9, 2023, 8:00 AM EST - 1 year ago

Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 8, 2023, 8:00 AM EST - 1 year ago

Edgewise Therapeutics to Present at Upcoming Investor Conferences

Nov 1, 2023, 8:00 AM EDT - 1 year ago

Edgewise to Present Data on EDG-7500 at the American Heart Association's Scientific Sessions 2023

Oct 26, 2023, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne)

Sep 27, 2023, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics to Present on EDG-5506 for Becker Muscular Dystrophy at the 28th International Annual Congress of the World Muscle Society

Sep 26, 2023, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker)

Sep 14, 2023, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction

Aug 10, 2023, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jun 26, 2023, 4:01 PM EDT - 1 year ago

Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

Jun 6, 2023, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics to Present at the Goldman Sachs Global Healthcare Conference

May 11, 2023, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Mar 30, 2023, 4:01 PM EDT - 1 year ago

Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD)

Mar 29, 2023, 7:28 AM EDT - 1 year ago

Top 5 Health Care Stocks That Preparing To Pump This Quarter - Enovis (NYSE:ENOV), Esperion Therapeutics (NASDAQ:ESPR)

ENOV ESPR SENS SLS

Mar 21, 2023, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023

Mar 14, 2023, 8:00 AM EDT - 2 years ago

Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference